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Background: Acute exacerbations of COPD (AECOPD) are common and strongly influence disease severity and
relative healthcare costs. Vitamin D deficiency is frequent among COPD patients and its contributory role in disease
exacerbations is widely debated. Our aim was to assess the relationship of serum vitamin D levels with COPD
severity and AECOPD.
Methods: Serum vitamin D (25-hydroxyvitamin D) levels were measured in 97 COPD patients and related to lung
function, comorbidities, FEV1 decline, AECOPD and hospital admission during the previous year.
Results: Most patients (96%) had vitamin D deficiency, which was severe in 35 (36%). No significant relationship
was found between vitamin D and FEV1 or annual FEV1 decline. No difference between patients with and without
severe vitamin D deficiency was found in age, gender, BMI, smoking history, lung function, and comorbidities, apart
from osteoporosis (60.9% in severe deficiency vs 22.7%, p = 0.001). In multiple logistic regression models, severe
deficiency was independently associated with AECOPD [adjusted odds ratios (aOR) of 30.5 (95% CI 5.55, 168), p <
0.001] and hospitalization [aOR 3.83 (95% CI 1.29, 11.4), p = 0.02]. The odds ratio of being a frequent exacerbator if
having severe vitamin D deficiency was 18.1 (95% CI 4.98, 65.8) (p < 0.001), while that of hospitalization was 4.57
(95% CI 1.83, 11.4) (p = 0.001).
Conclusions: In COPD patients severe vitamin D deficiency was related to more frequent disease exacerbations
and hospitalization during the year previous to the measurement of vitamin D. This association was independent of
patients’ characteristics and comorbidities.
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The prevalence of COPD is increasing and this has a
heavy influence on healthcare costs [1], particularly be-
cause of the frequent disease exacerbations (AECOPD)
and hospital admissions. The disease control is far from
being reached and dietary factors are acknowledged as
one of the several factors contributing to COPD [2].
Vitamin D deficiency was highly prevalent in a general
US population in the third National Health and* Correspondence: caterina.bucca@unito.it
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article, unless otherwise stated.Examination Survey [3]. According to Janssens et al. [4],
vitamin D deficiency occurs in over 60% of patients with
severe COPD, and is quantitatively related to disease se-
verity. Epidemiological studies indicate that decreased
vitamin D is associated with increased frequency of re-
spiratory infections not only in COPD patients, but also in
healthy people [4,5]. This may be due to the involvement
of vitamin D in both innate and adaptive immunity regula-
tion [6,7]. A general population study by Skaaby et al. [8],
demonstrated a significant inverse association between
vitamin D status and death caused by diseases of the re-
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vitamin D in AECOPD is still debated. In a secondary ana-
lysis of a study performed in exacerbation-prone COPD
patients [9], no association between baseline vitamin D
levels and subsequent risk of acute exacerbations was
found; negative results have also been reported in a pri-
mary care setting [10]. A single center randomized trial on
182 COPD patients [11] demonstrated that vitamin D sup-
plements were able to reduce COPD exacerbations only in
the 30 subjects with severe deficiency. These findings leave
open the question of the role of vitamin D deficiency and
the benefit of its correction in COPD.
We performed a retrospective observational cohort
study in COPD patients not taking vitamin D supple-
ments, to evaluate if low vitamin D levels is associated
with severe airway obstruction, annual FEV1 decline,
disease exacerbations and hospital admission over the
course of one year.Materials and methods
Patients were selected among 229 consecutive COPD
patients, with any range of severity according to the
GOLD classification [2], who presented for a scheduled
visit at our Respiratory Clinic during the period October
2011-March 2012. Inclusion criteria were age over
40 years, a post-bronchodilator ratio of forced expiratory
volume in 1 second (FEV1) to vital capacity (VC) <0.7,
and at least one year follow-up in our clinic. Exclusion
criteria were AECOPD in the last month (n = 19),
current treatment with vitamins and dietary supplements
(n = 46) and lack of availability for data on lung func-
tion/exacerbations/hospitalization the year previous to
the inclusion in the study (n = 67), resulting therefore in
97 patients to be included in the study.
The study was approved by the Institutional Review
Board (CEI N. 414) and written informed consent was
obtained from each patient.
At the enrolment visit, patients underwent clinical
examination, recording of symptoms, smoking habits,
medication use, lung function tests, venous blood sam-
pling for nutritional assessments. Subjects were classified
as current, former- and never-smokers, according to self-
reported smoking history. Body mass index (BMI) was cal-
culated as weight divided by height squared (kg/m2).
Comorbidities were recorded on the basis of prior
diagnosis and current treatment for: systemic arterial
hypertension, diabetes, dyslipidemia, anxiety and/or de-
pression, chronic kidney disease, cerebrovascular disease,
osteoporosis, obstructive sleep apnoea (OSA), any type
of active malignant tumor. The diagnosis of pulmonary
hypertension, heart disease and chronic heart failure had
to be supported by symptoms and clinical and echocar-
diographic examination [12].The medical records of the patients were collected and
reviewed retrospectively, to gain information relative to
the previous year:
– annual FEV1 decline: difference between actual
FEV1 and FEV1 recorded 12 months before.
– annual number of AECOPD, defined on the basis of
unscheduled visits in our clinic for acute worsening
of respiratory symptoms, causing changes or
increases in medications, use of antibiotics or oral
steroids, and/or requiring hospitalization [13,14].
Patients with two or more AECOPDs were defined
as frequent exacerbators [15].
– hospital admission for AECOPD in the last year
Lung function tests were measured using the Baires Sys-
tem (Biomedin, Padua, Italy). The values of VC, FEV1,
FEV1/VC ratio, and maximal midexpiratory flow-rate
(MEF50) were computed. VC, FEV1 and MEF50 were
expressed as% of the predicted value [16]. Annual FEV1 de-
cline was calculated as percent of the pre-bronchodilator
starting value.
Nutritional assessment consisted of: serum levels of fer-
ritin, folic acid and vitamin B12, measured using the
chemiluminescent micro-particle immunoassay (Architect
System, Abbott diagnostic division, Longford, Ireland),
vitamin D (25-hydroxyvitamin D) levels, measured by
the RIA method (25OH Vitamin D total-Ria-CT Kit, DIA-
source ImmunoAssay S.A., Louvain, Belgium). Vitamin D
levels were regarded as normal (≥30 ng/ml), mild-
moderate deficiency ( ≥10, but <30 ng/ml), severe defi-
ciency (<10 ng/ml) [17].
Statistical analysis
All statistics were performed with STATA/IC 12.1
(StataCorp LP, College station, TX, USA) with the excep-
tion of calculation of confidence intervals for sensitivity
and specificity at different cut-off levels that was per-
formed with GraphPad Prism v 6.0 (GraphPad Software,
San Diego, CA, USA).
Pearson’s chi-squared test was used to compare the
prevalence of categorical variables between groups (2 or
more groups). t-test or Mann-Whitney-test was used to
compare differences in the levels of continuous variables
between 2 groups (e.g. males vs females or subjects with
and without severe vitamin D deficiency).
Linear regression analyses were performed to analyze the
association between (log-transformed) vitamin D levels and
lung function indices. These associations were tested in
multiple linear regression models after adjustments for po-
tential confounders.
Logistic regression analysis models were used to calcu-
late odds ratios (simple models) or adjusted odds ratios
(aOR) for severe vitamin D deficiency in relation to
Table 1 Characteristics of the overall patients and
by gender
Variable All patients Men Women
(n = 97) (n = 49) (n = 48)
Age median (range) 67.5 +/- 10.5 69.1 +/- 10.5 65.8 +/- 10.4
BMI (mean +/- SD) 25.5 ± 5.20 26.3 ± 4.4 24.7 ± 5.8
Smoking habits
• Current smokers n (%) 60 (61.9%) 27 (55.1) 33 (68.8)
• Former smokers n (%) 22 (22.7%) 18 (36.7) 4 (8.3)*
• Never smokers n (%) 15 (15.6%) 4 (8.2) 11 (22.9)*
GOLD class n (%)
• 1 18 (18.6) 9 (18.4) 9 (18.8)
• 2 55 (56.7) 27 (55.1) 28 (58.3)
• 3 20 (20.6) 12 (24.5) 8 (16.7)
• 4 4 (4.1) 1 (2.0) 3 (6.3)
Medication for COPD n (%)
• None 6 (7.4) 1 (2.4) 5 (12.5)
• Long Acting Muscarinic
Antagonist (LAMA)
53 (55) 28 (57) 25 (52)
• Long Acting Beta
Adrenergic (LABA)
64 (66) 35 (71) 29 (60)
• Inhaled Corticosteroids (ICS) 61 (63) 35 (71) 26 (54)
AECOPD/year, median (IQR) 2 (1-2) 2 (1-2) 2 (1-2.5)
Frequent exacerbators n (%) 55 (56.7) 25 (51.0) 30 (62.5)
Hospitalized for AECOPD
in the last year, n (%)
50 (51.6) 25 (51.0) 25 (52.0)
FEV1%pred, mean ± SD 62.3 ± 18.0 62.4 ± 17.3 62.2 ± 18.9
VC%pred, mean ± SD 83.1 ± 18.1 82.0 ± 18.3 84.1 ± 18.0
FEV1/VC%, mean ± SD 53.8 ± 11.4 54.0 ± 11.5 53.6 ± 11.4
MEF50% pred, mean ± SD 28.8 ± 21.4 28.8 ± 20.6 28.8 ± 22.4
*Significant difference (p < 005) between men and women.
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COPD. MEF50 was the only lung function parameter in-
cluded in the models as it had the strongest relationship
with vitamin D levels in univariate models. Interaction
of severe vitamin D deficiency with gender on the asso-
ciation with being a frequent exacerbator or hospitalized
were also tested in the multiple logistic regressions.
Receiver-operator characteristic (ROC)-analyses were
performed to identify the value of vitamin D with the
best combination of specificity and sensitivity in pre-
dicting frequent exacerbations and hospitalization for
COPD. Several cut-offs are presented: for high sensitivity,
high specificity and optimal cut-off, according to the You-
den index [18].
Two multiple regression models were created: one in-
cluding only patient characteristics, the other including
also comorbidities and nutritional data. For all the re-




General characteristics of the study patients and by sex,
are given in Table 1; comorbidities and nutritional data
are reported in Table 2. The study population was
gender-balanced, the majority of subjects (62%) were
current smokers. More than half of the patients (57%)
were in moderate GOLD class, 55% were frequent
exacerbators and 52% had been hospitalized at least
once in the previous year. The most frequent comorbidi-
ties were hypertension and heart disease (HD), found in
almost two thirds of the subjects. Vitamin D deficiency
(<30 ng/mL) was found in all but four patients and was
severe in 36% of them.
Women, as compared to men, had higher prevalence
of never smokers, severe vitamin D deficiency, thyroid
disease, hypertension, valvular heart disease, and a trend
towards a larger number of AECOPD (p = 0.07).
The comparison between patients with (n = 35) and
without severe (n = 62) vitamin D deficiency showed no
significant difference regarding age, BMI, smoking his-
tory and comorbidities (all p-values over 0.10) apart
from osteoporosis, significantly more frequent in severe
deficiency (60.9% vs 22.7%, p = 0.001). Likewise, no sig-
nificant difference was found in FEV1% predicted (p =
0.27), GOLD class (p = 0.16), and VC% predicted (p =
0.49); however, subjects with severe deficiency had sig-
nificantly lower MEF50 (22.3 +/- 15.8% vs 32.5 +/-
23.3%, p = 0.02) and a trend toward lower FEV1/VC ratio
(51.2% +/- 11.5% vs. 55.3% +/ 11.2, p = 0.09).
As shown in Figure 1, vitamin D levels were not re-
lated to FEV1% predicted (p = 0.20) (Figure 1A) and VC
% predicted (p = 0.38) (Figure 1B), but were significantly
negatively related to MEF50 levels (p = 0.02) (Figure 1C)and FEV1/VC ratio (p = 0.02) (Figure 1D). However, after
adjusting for gender, age, BMI and smoking habits, all
the relationships presented in Figure 1, all relations were
not significant (p > 0.05), and remained so also after fur-
ther adjustment for comorbidities (p > 0.05).
No significant relation could be found between vita-
min D levels and fall in FEV1 during the year preceding
vitamin D measurements, expressed either as absolute
levels (p = 0.20) or as percent fall (p = 0.09), even after
adjusting for gender, age, BMI and current smoking (p =
0.35 for absolute value and p = 0.26 for FEV1% fall).
Levels of FEV1 fall were similar in subjects with and
without severe vitamin D deficiency (p = 0.51 for abso-
lute and p = 0.36 for percent fall).
An analysis of vitamin D levels stratified by number of
exacerbations in the year preceding the study entry
showed that the higher the number of AECOPD the lower
the vitamin D level (p < 0.001) (Figure 2A). This relation
persisted after adjusting for gender, age, smoking habits,
Table 2 Comorbidities and nutritional status in the overall patients and by gender
Variable All patients Men Women
(n = 97) (n = 49) (n = 48)
Hypertension n (%) 59 (62.1) 25 (51) 34 (70.8)*
Heart disease (any*) n (%) 64 (67.4) 29 (59.2) 35 (72.9)
• Hypertensive n (%) 26 (27.4) 13 (26.5) 13 (27.1)
• Ischemic n (%) 19 (20.0) 12 (24.5) 7 (14.6)
• Heart failure n (%) 48 (50.5) 24 (49.0) 24 (50.0)
• Valvular n (%) 33 (34.7) 12 (24.5) 21 (43.8)*
• Atrial fibrillation n (%) 22 (23.2) 12 (24.5) 10 (20.8)
Pulmonary hypertension n (%) 23 (24.2) 10 (20.4) 13 (27.1)
Dyslipidemia n (%) 33 (34.7) 15 (30.6) 18 (37.5)
Thyroid disease n (%) 20 (20.6) 5 (10.2) 15 (31.3)*
Diabetes n (%) 15 (15.8) 8 (16.3) 7 (14.6)
Cerebrovascular disease n (%) 11 (11.3) 8 (16.3) 3 (6.3)
Renal failure n (%) 17 (20.2) 10 (20.4) 7 (14.6)
Osteoporosis n (%) 23 (25.8) 8 (16.3) 15 (31.3)
Cancer n (%) 17 (17.7) 11 (22.9) 6 (12.5)
Depression/anxiety n (%) 28 (29.5) 11 (22.4) 17 (35.4)
GERD n (%) 15 (16.7) 5 (10.2) 10 (20.8)
Obstructive sleep apnea n (%) 11 (12.4) 5 (10.2) 6 (12.5)
Nutrition parameters
Vitamin D levels (ng/ml) (GM (95%CI)] 12.0 (10.6 - 13.5) 15.5 (12.7-18.4) 12.7 (10.9-14.6)
Mild-moderate deficiency n (%) 58 (57.9%) 31 (63.3) 27 (56.3)
Severe deficiency n (%) 35 (36.1%) 14 (28.6) 21 (43.8)*
Ferritin deficiency (<25 mg/dl) n (%)# 10 (11.1%) 4 (8.5) 6 (14.0)
Vitamin B12 deficiency (<200 pg/ml) n (%)# 19 (20.2%) 11 (22.9) 8 (17.4)
Folic acid deficiency (<4.5 ng7ml) n (%)# 33 (35.9%) 16 (34.0) 17 (37.8)
*Data on comorbidities available in 84 to 97 subjects, depending on comorbidity.
#Ferritin levels measured in 90 subjects, Vitamin B12 in 94 subjects, Folic acid in 92 subjects.
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adjusting for other nutritional deficiencies and comorbidi-
ties (p < 0.001). Similarly, the proportion of subjects with
severe vitamin D deficiency increased with the number of
AECOPD (p < 0.001) (Figure 2B).
The prevalence of severe vitamin D deficiency was lar-
ger among frequent than among non-frequent exacerba-
tors (58.2% versus 7.1%, p < 0.001). The odds ratio of
being a frequent exacerbator if having severe vitamin D
deficiency was 18.1 (95% CI 4.98, 65.8) (p < 0.001). Severe
vitamin D deficiency was independent of frequent exacer-
bations [adjusted OR = 30.5 (95% CI 5.55, 168), p < 0.001]
in a multiple logistic regression model after adjusting for
gender, age, BMI, smoking, lung function (MEF50), even
after further adjusting for nutritional deficiencies [adjusted
OR= 34.9 (95% CI 4.89, 249), p < 0.001]. No interaction
between severe vitamin D deficiency and gender was
found in this model (p = 0.84). The relation between se-
vere vitamin D deficiency and frequent exacerbations wasconsistent after further adjusting for all the comorbidities
(p = 0.03).
A total of 50 subjects (51.5%) were hospitalized for
AECOPD at least once during the year preceding vita-
min D measurement. These subjects had significantly
lower vitamin D levels (p < 0.001) (Figure 3A). and
higher prevalence of severe vitamin D deficiency (p =
0.001) (Figure 3B). Lower levels of vitamin D were associ-
ated with hospitalization (p < 0.001) after adjusting for
gender, age, BMI, smoking, lung function (MEF50) (p =
0.002), and the association persisted after further adjusting
for comorbidities (p = 0.001). No differences in vitamin D
levels (p = 0.74) or prevalence of severe vitamin D defi-
ciency (p = 0.85) were found between subjects hospitalized
once (n = 34) or twice (n = 16) during the preceding year.
ROC curve for vitamin D levels in relation to frequent
exacerbations yielded an area under the curve (AUC) of
0.83 (95% CI 0.75, 0.91) (Additional file 1: Figure S1). The
optimal cut-off (according to Youden index) to identify
Figure 1 Lung function parameters: FEV1 (%predicted) (A), VC (% predicted) (B), MEF50 (% predicted) (C), FEV1/VC (×100) (D) in relation
to vitamin D levels (log-scale).
Malinovschi et al. Respiratory Research 2014, 15:131 Page 5 of 8
http://respiratory-research.com/content/15/1/131frequent exacerbators was 9.15 ng/mL (Additional file 2:
Table S1). All the subjects (n = 27) with vitamin D levels
below 8.65 ng/mL were frequent exacerbators, while 9 of
10 subjects with two or more AECOPD in the last year
had vitamin D levels below 19.15 ng/mL (Additional file 2:
Table S1). Similarly, low vitamin D was associated withFigure 2 Levels of vitamin D (log-scale) in COPD subjects divided acc
measurements of vitamin D levels (A) and the proportion of subjects
divided according to the number of exacerbations the year previousany AECOPD [AUC= 0.81 (95% CI 0.71, 0.91)] and all
subjects with vitamin D levels below 11.7 ng/mL had at
least one AECOPD during the year preceding the study
(Additional file 2: Table S2).
The odds ratio of being hospitalized if having severe
vitamin D deficiency was 4.57 (95% CI 1.83, 11.4) (p =ording to the number of exacerbations the year previous to the
with severe vitamin D deficiency (<10 ng/mL) in COPD subjects
to the measurements of vitamin D levels (B).
Figure 3 Levels of vitamin D (A) or prevalence of severe vitamin D deficiency (B) in COPD subjects divided according to being
hospitalized the year previous to the measurements of vitamin D levels.
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related with hospitalizations [aOR 3.83 (95% CI 1.29,
11.4)] after adjusting for gender, age, BMI, smoking and
lung function (MEF50) (p = 0.01). This effect was consist-
ent after further adjustment for nutritional deficiencies
[adjusted OR 8.45 (95% CI 1.82, 39.2), p = 0.006] and no
interaction between severe vitamin Ddeficiency and gen-
der was found in this model (p = 0.50). The relationship
between severe vitamin D deficiency and hospitalization
was consistent even after adjusting for comorbidities
(p = 0.02).
ROC curve for vitamin D levels in relation to
hospitalization yielded an AUC of 0.75 (0.65, 0.84)
(Additional file 3: Figure S2). The optimal cut-off value
to identify subjects hospitalized for AECOPD was
12.2 ng/ml, and 9 out of 10 subjects who had been hos-
pitalized during the last year had vitamin D levels below
19.15 ng/mL (Additional file 2: Table S3).
Discussion
The results of the study demonstrate that most COPD
patients had vitamin D deficiency. Severe deficiency was
associated with frequent exacerbations, documented in
our clinic, and hospitalization during the previous year.
These findings were consistent even after adjustments for
comorbidities and other nutrient deficiencies. Vitamin
D levels were not related to either lung function at
the study enrolment or lung function decline in the
preceding year.
Vitamin D deficiency represented the major nutritional
disorder in our study population, being mild-moderate in
about 60% and severe in as high as 36% of the patients. A
high prevalence of vitamin D deficiency in COPD patients
has been previously reported [4,9,11,19], but never as high
as in our patients. This may depend on several reasons.
First, vitamin D was deliberately assessed in the winter
season, when levels are supposed to be lowest [20], espe-
cially to the latitude of our city [21,22]. Anyway, it is pre-
sumable that our subjects were deficient throughout theyear, as in Italy, at variance with other countries [23], there
is no food fortification with vitamin D. It has been esti-
mated that a summer vitamin D level around 40 ng/mL is
needed to achieve a 20 ng/mL concentration the following
winter [24] and similar variations appear to exist in COPD
patients, with approximately 35% lower values in winter
compared to summer [25]. The lowest winter vitamin D
values may contribute to the marked impact of winter sea-
son on both frequency and outcomes of COPD exacerba-
tions [26,27].
These findings are in agreement with prior obser-
vations that low vitamin D levels are associated with
increased frequency of respiratory infections in both
COPD patients and healthy adults [4,5,28]. However, the
role of vitamin D deficiency in AECOPD is still debated.
A recent study on exacerbation-prone COPD patients
found no association between baseline vitamin D levels
and subsequent risk of AECOPD [9]. However, accord-
ing to Heulens et al. [29], this negative finding might de-
pend on the fact that some of the patients with worse
clinical conditions were taking vitamin D supplements.
Of course, once supplemented, vitamin D levels no lon-
ger reflect the underlying COPD severity. Actually, ex-
cluding those taking supplements from the analysis,
Heulens et al. [29] could demonstrate that patients with
vitamin D levels below 10 ng/ml had the shortest time
to first exacerbation and experienced the highest num-
ber of AECOPD. Moreover, pooling together patients
with vitamin D levels ranging from 10 to 30 ng/ml, they
found a dose–response relationship for exacerbations
number very similar to that found in our study. Another
recent study by Puhan et al. [10] reported no relation of
severe vitamin D deficiency with exacerbations and no
effect of vitamin D supplements on AECOPD. Such
negative result may depend on several reasons. First,
vitamin D deficiency was less severe than that observed
in our study patients (15.5 versus 12 ng/dl). Second, al-
though patients taking vitamin D supplements had been
excluded at enrolment, it was not specified if patients
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thermore, different vitamin D assays were used in these
studies and this could, at least in theory, yield different
results and therefore vitamin D levels in absolute values
might be more difficult to compare between studies. A
recent study on 12,041 individuals from the Danish gen-
eral population by Skaaby et al. [30], found that vitamin
D status was significantly inversely associated with
COPD but had no influence on COPD incidence. This
finding suggests that vitamin D deficiency is a conse-
quence rather than a cause of COPD. The effect of vita-
min D supplementation in COPD is still debated. High
dose vitamin D supplementation has been found to to
decrease AECOPD number, but only in patients with se-
vere deficiency [11] and to improve inspiratory muscle
strength and maximal oxygen uptake [31].
At variance with other findings [19,32], in our patients
vitamin D levels were not related to FEV1 and to the
GOLD-COPD class, which is based on FEV1 value, nei-
ther were they predictive of FEV1 decline. This could
simply be due to the fact that the size of such effect is so
small that a larger population would have been needed
to demonstrate it. Actually, both the studies of Persson
et al. [19] and Berg et al. [32] had populations about five
times larger than ours, and patients were well distrib-
uted among the GOLD classes, while most of our pa-
tients were in GOLD class II. Interestingly, in univariate
analysis the levels of vitamin D were significantly related
to both FEV1/VC and MEF50, but these correlations dis-
appeared after adjustments for potential confounders.
The major weakness of the present study was its retro-
spective design, as the vitamin D levels were measured
at the end of the observation period, where events (exac-
erbations) and lung function decline were recorded.
Therefore a potential reverse causation effect, with exac-
erbations lowering levels of vitamin D, cannot be ex-
cluded even if no such relation has been described in
the literature [25]. Furthermore, a study in independ-
ently living community-dwelling subjects of similar age,
with different degrees of vitamin D deficiency, reported
steady levels over a one year period [33] and therefore it
might be speculated that the levels of vitamin D mea-
sured in the present study could be similar to the previ-
ous year values. However, in our opinion, a retrospective
study, as compared to a prospective one, avoids the criti-
cism of not treating patients with severe deficiency.
Conclusions
The results of the present study demonstrate that vita-
min D deficiency is very common in COPD patients,
and indicate that severe deficiency is associated with
higher probability having frequent exacerbations and
hospitalization and this association is independent of pa-
tient characteristics and comorbidities. The preventionof exacerbations is a major treatment goal of COPD and
the benefit of vitamin D supplementation, particularly
during the winter season, is an intervention that war-
rants further assessment. However randomized con-
trolled trials are needed to clarify whether the observed
association in the present study is causal and is really at-
tributable to vitamin D deficiency.
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